AngioDynamics - ANGO Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" ANGO shares.
View ANGO analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 12 month price targets for AngioDynamics' shares. Their ANGO share price forecasts range from $22.00 to $35.00. On average, they anticipate the company's stock price to reach $28.50 in the next year. This suggests a possible upside of 111.7% from the stock's current price.
View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts.

AngioDynamics' stock was trading at $13.77 at the beginning of 2023. Since then, ANGO shares have decreased by 2.3% and is now trading at $13.46.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 6th 2023.
View our ANGO earnings forecast.

AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings results on Thursday, January, 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The medical instruments supplier had revenue of $85.43 million for the quarter, compared to analyst estimates of $84.05 million. AngioDynamics had a negative trailing twelve-month return on equity of 0.14% and a negative net margin of 9.98%.

AngioDynamics updated its FY23 earnings guidance on Thursday, January, 5th. The company provided earnings per share guidance of $0.01-0.06 for the period, compared to the consensus EPS estimate of $0.01. The company issued revenue guidance of $342-346 million, compared to the consensus revenue estimate of $342.48 million.

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics' stock is owned by a number of institutional and retail investors. Top institutional investors include Lapides Asset Management LLC (0.55%), Assenagon Asset Management S.A. (0.37%), Allspring Global Investments Holdings LLC (0.32%), Keybank National Association OH (0.06%), Yousif Capital Management LLC (0.06%) and Comerica Bank (0.06%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends.

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANGO stock can currently be purchased for approximately $13.46.

AngioDynamics (NASDAQ:ANGO) has a market capitalization of $526.69 million and generates $316.22 million in revenue each year. The medical instruments supplier earns $-26,550,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

The company employs 800 workers across the globe.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401.